- Home
- CARS vs LXEO Comparison
CARS vs LXEO Comparison
Compare CARS & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CARS | LXEO |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Motor Vehicles | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 724.3M | 663.5M |
| IPO Year | 2017 | 2023 |
Fundamental Metrics
Financial Performance| Metric | CARS | LXEO |
|---|---|---|
| Price | $12.45 | $10.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $17.70 | ★ $18.90 |
| AVG Volume (30 Days) | 896.2K | ★ 1.5M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $719,767,000.00 | N/A |
| Revenue This Year | $2.49 | N/A |
| Revenue Next Year | $3.17 | N/A |
| P/E Ratio | $27.07 | ★ N/A |
| Revenue Growth | ★ 0.20 | N/A |
| 52 Week Low | $9.56 | $1.45 |
| 52 Week High | $19.00 | $10.99 |
Technical Indicators
Market Signals| Indicator | CARS | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 51.95 | 57.21 |
| Support Level | $11.85 | $10.32 |
| Resistance Level | $13.69 | $10.99 |
| Average True Range (ATR) | 0.41 | 0.61 |
| MACD | -0.07 | 0.06 |
| Stochastic Oscillator | 33.97 | 60.77 |
Price Performance
Historical ComparisonAbout CARS Cars.com Inc.
Cars.com Inc is an online destination for buying and selling new and used vehicles. It is an audience-driven technology company empowering the automotive industry. The company brands include Dealer Inspire, DealerRater, FUEL, Accu-Trade, PickupTrucks.com, CreditIQ, and NewCars.com., websites directed towards different consumer segments.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.